DENVER , Aug. 6, 2024 /PRNewswire/ -- DaVita Inc. (NYSE: DVA ) announced financial and operating results for the quarter ended June 30, 2024.
"On behalf of all the teammates who provide life-saving care to our patients, I am grateful for the opportunity to report another positive quarter for DaVita," said Javier Rodriguez , CEO of DaVita Inc. "We continue to enhance our clinical capabilities while optimizing our revenue operations and cost structure." Financial and operating highlights for the quarter ended June 30, 2024: Consolidated revenues were $3.
187 billion . Operating income was $506 million . Diluted earnings per share was $2.
50 and adjusted diluted earnings per share was $2.59 . Operating cash flow was $799 million and free cash flow was $654 million .
Extended the maturity date for a portion of Term Loan B-1 in the aggregate principal amount of $1.64 billion . Repurchased 2.
7 million shares of our common stock at an average price paid of $140.14 per share. U.
S. dialysis metrics: Volume: Total U.S.
dialysis treatments for the second quarter of 2024 were 7,265,444, or an average of 93,147 treatments per day, representing a per day increase of 1.1% compared to the first quarter of 2024. Normalized non-acquired treatment growth in the second quarter of 2024 compared to the second quarter of 2023 was 0.
4%. Primary drivers of the changes in the table above were as follows: Revenue: The quarter change was primarily due to a seasonal improvement from patients meeting their .